PANACEABIO Stock Overview
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PANACEABIO from our risk checks.
Panacea Biotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹143.65 |
| 52 Week High | ₹202.50 |
| 52 Week Low | ₹114.20 |
| Beta | 0.74 |
| 1 Month Change | 16.32% |
| 3 Month Change | -12.03% |
| 1 Year Change | 18.28% |
| 3 Year Change | -56.71% |
| 5 Year Change | -24.95% |
| Change since IPO | 141.02% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S
Apr 04
Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All
Sep 23Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)
Jul 28How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?
Feb 14Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years
Jan 06Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?
Sep 17
If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today
Aug 03Shareholder Returns
| PANACEABIO | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | 5.3% | 8.7% | 2.8% |
| 1Y | 18.3% | 23.9% | 46.6% |
Return vs Industry: PANACEABIO underperformed the Indian Biotechs industry which returned 23.9% over the past year.
Return vs Market: PANACEABIO underperformed the Indian Market which returned 46.6% over the past year.
Price Volatility
| PANACEABIO volatility | |
|---|---|
| PANACEABIO Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: PANACEABIO has not had significant price volatility in the past 3 months.
Volatility Over Time: PANACEABIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,794 | Rajesh Jain | www.panaceabiotec.com |
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, and gastro-intestinal care; and pneumococcal vaccine, dengue tetravalent vaccine, typhoid conjugate vaccine, and universal flu vaccine.
Panacea Biotec Limited Fundamentals Summary
| PANACEABIO fundamental statistics | |
|---|---|
| Market cap | ₹8.80b |
| Earnings (TTM) | -₹116.77m |
| Revenue (TTM) | ₹5.52b |
1.6x
P/S Ratio-75.4x
P/E RatioIs PANACEABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PANACEABIO income statement (TTM) | |
|---|---|
| Revenue | ₹5.52b |
| Cost of Revenue | ₹2.38b |
| Gross Profit | ₹3.14b |
| Other Expenses | ₹3.25b |
| Earnings | -₹116.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | 56.88% |
| Net Profit Margin | -2.12% |
| Debt/Equity Ratio | 2.5% |
How did PANACEABIO perform over the long term?
See historical performance and comparison